 | | | Vol. 14.41 – 3 November, 2022 |
|
|
|
| MYC-mediated suppression of inflammatory signaling induced by BRCA1/2 inactivation was confirmed in human TNBC cell lines.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors reported that FOXQ1 initiated epithelial-mesenchymal transition by recruiting the MLL/KMT2 histone methyltransferase complex as a transcriptional coactivator.
[Nature Communications] |
|
|
|
| Scientists systematically tracked estrogen response across time at a single-cell level in multiple cell line and organoid models, and developed a computational tool that quantified signaling gradients in single-cell datasets.
[Nucleic Acids Research] |
|
|
|
| Researchers identified the long noncoding RNA, LINC00589 as a key regulatory node for concurrent intervention of multiple chemoresistance and cancer stem cell-like properties in breast cancer cells in vitro and in vivo.
[npj Breast Cancer] |
|
|
|
| Scientists found that knockdown of B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) significantly suppressed cell proliferation and migration in vitro and vivo.
[Cancer Science] |
|
|
|
| The authors used cell-based, either in 2D or 3D conditions, and in vivo experiments to understand the serine beta-lactamase-like (LACTB) protein mechanisms.
[Apoptosis] |
|
|
|
|
| Investigators discuss the diverse roles of free-fatty acids (FFA)1 and FFA4 in the regulation of cell proliferation, migration, invasion, and chemotherapy resistance in human breast carcinoma cells and tissue.
[Biochemical Pharmacology] |
|
|
|
| The authors organize and present the literature from the last five years investigating the mechanisms and implications of adipokine signaling in breast, endometrial, and ovarian cancers with a special focus on leptin and adiponectin.
[Annals of the New York Academy of Sciences] |
|
|
|
|
| Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca’s next-generation oral selective estrogen receptor degrader camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival benefit.
[AstraZeneca, Inc.] |
|
|
|
|
| December 7 – 9, 2022
Geneva, Switzerland |
|
|
|
|
|
| | Provincial Health Services Authority – Vancouver, British Columbia, Canada |
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | AstraZeneca – Mississauga, Ontario, Canada |
|
|
|
| | Nature Communications – London, Berlin, New York, Shanghai (Hybrid) |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
